26
Jun

German giant Boehringer Ingelheim is racing to the market with an antidote to its blockbuster blood-thinner Pradaxa, securing the FDA’s coveted breakthrough therapy designation for its in-development treatment.

…read more

Source: Boehringer bags a ‘breakthrough’ tag for its Pradaxa antidote

    

0 No comments